Literature DB >> 1580304

Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report.

J L Gomez1, A Dupont, L Cusan, M Tremblay, M Tremblay, F Labrie.   

Abstract

We report the case of a 69-year-old patient treated for stage C adenocarcinoma of the prostate with the combination of the luteinizing hormone-releasing hormone agonist [D-Trp6, des-Gly-NH2(10)] LHRH ethylamide and the antiandrogen nilutamide (Anandron) who developed simultaneous liver and lung toxicity. Investigation revealed an abnormal chest radiograph accompanied by altered respiratory function tests, suggesting the diagnosis of interstitial lung disease. This diagnosis was confirmed by an open chest biopsy. At the same time, liver function tests yielded abnormal results. All toxic manifestations disappeared after cessation of treatment with Anandron.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1580304     DOI: 10.1016/0002-9343(92)90756-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

Review 1.  Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.

Authors:  C Mahler; J Verhelst; L Denis
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

Review 2.  Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

Authors:  M G Harris; S G Coleman; D Faulds; P Chrisp
Journal:  Drugs Aging       Date:  1993 Jan-Feb       Impact factor: 3.923

3.  Nilutamide pneumonitis: a report on eight patients.

Authors:  P Pfitzenmeyer; P Foucher; F Piard; B Coudert; M L Braud; P Gabez; S Lacroix; J P Mabille; P Camus
Journal:  Thorax       Date:  1992-08       Impact factor: 9.139

4.  Microscopic polyangiitis complicated by the development of prostate cancer and flutamide-induced hepatitis.

Authors:  D Papaioannides; P Korantzopoulos; C Bouropoulos; P Latsi; M Fotinou; D Orphanidou
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.266

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.